These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

424 related items for PubMed ID: 15188371

  • 1. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
    Kaltwasser JP, Nash P, Gladman D, Rosen CF, Behrens F, Jones P, Wollenhaupt J, Falk FG, Mease P, Treatment of Psoriatic Arthritis Study Group.
    Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
    [Abstract] [Full Text] [Related]

  • 2. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.
    Nash P, Thaçi D, Behrens F, Falk F, Kaltwasser JP.
    Dermatology; 2006 Jun; 212(3):238-49. PubMed ID: 16549920
    [Abstract] [Full Text] [Related]

  • 3. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
    Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, Furst DE, Molitor J, Keystone E, Gladman D, Manger B, Wassenberg S, Weier R, Wallace DJ, Weisman MH, Kalden JR, Smolen J.
    Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
    Poór G, Strand V, Leflunomide Multinational Study Group.
    Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
    [Abstract] [Full Text] [Related]

  • 5. Leflunomide in psoriatic arthritis.
    Kaltwasser JP.
    Autoimmun Rev; 2007 Sep; 6(8):511-4. PubMed ID: 17854740
    [Abstract] [Full Text] [Related]

  • 6. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group.
    Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, Thompson A, Wells G.
    Arthritis Rheum; 1999 Sep; 42(9):1870-8. PubMed ID: 10513801
    [Abstract] [Full Text] [Related]

  • 7. A comparison of the efficacy and safety of celecoxib 200 mg and celecoxib 400 mg once daily in treating the signs and symptoms of psoriatic arthritis.
    Kivitz AJ, Espinoza LR, Sherrer YR, Liu-Dumaw M, West CR.
    Semin Arthritis Rheum; 2007 Dec; 37(3):164-73. PubMed ID: 17570469
    [Abstract] [Full Text] [Related]

  • 8. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial.
    Torii H, Nakagawa H, Japanese Infliximab Study investigators.
    J Dermatol Sci; 2010 Jul; 59(1):40-9. PubMed ID: 20547039
    [Abstract] [Full Text] [Related]

  • 9. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
    Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landewé R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ.
    Ann Rheum Dis; 2005 Jun; 64(6):859-64. PubMed ID: 15528283
    [Abstract] [Full Text] [Related]

  • 10. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Keystone EC, Loveless JE, Burmester GR, Cravets MW, Hessey EW, Shaw T, Totoritis MC, REFLEX Trial Group.
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [Abstract] [Full Text] [Related]

  • 11. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
    Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, IMPACT 2 Trial Investigators.
    Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
    [Abstract] [Full Text] [Related]

  • 12. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, Kvien TK, Jones P, Williams RB, Oed C, Rosenburg R, European Leflunomide Study Group.
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [Abstract] [Full Text] [Related]

  • 13. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.
    Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA, Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.
    Arthritis Rheum; 2005 Oct; 52(10):3279-89. PubMed ID: 16200601
    [Abstract] [Full Text] [Related]

  • 14. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
    Mease PJ, Gladman DD, Keystone EC, Alefacept in Psoriatic Arthritis Study Group.
    Arthritis Rheum; 2006 May; 54(5):1638-45. PubMed ID: 16646026
    [Abstract] [Full Text] [Related]

  • 15. Abatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial.
    Mease P, Genovese MC, Gladstein G, Kivitz AJ, Ritchlin C, Tak PP, Wollenhaupt J, Bahary O, Becker JC, Kelly S, Sigal L, Teng J, Gladman D.
    Arthritis Rheum; 2011 Apr; 63(4):939-48. PubMed ID: 21128258
    [Abstract] [Full Text] [Related]

  • 16. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life.
    De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S.
    J Dermatolog Treat; 2006 Apr; 17(6):355-8. PubMed ID: 17853309
    [Abstract] [Full Text] [Related]

  • 17. Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial.
    Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, Luggen M, Keystone E, Bathon J, Kavanaugh A, Ruderman E, Coleman P, Curtis D, Kopp E, Kantor S, Weisman M, Waltuck J, Lindsley HB, Markenson J, Crawford B, Fernando I, Simpson K, Strand V.
    J Rheumatol; 2004 Aug; 31(8):1521-31. PubMed ID: 15290730
    [Abstract] [Full Text] [Related]

  • 18. Leflunomide in the treatment of psoriasis: results of a phase II open trial.
    Tlacuilo-Parra JA, Guevara-Gutiérrez E, Rodríguez-Castellanos MA, Ornelas-Aguirre JM, Barba-Gómez JF, Salazar-Páramo M.
    Br J Dermatol; 2004 May; 150(5):970-6. PubMed ID: 15149511
    [Abstract] [Full Text] [Related]

  • 19. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D, Park GS, Paulus HE, Simpson KM, Elashoff D, Cohen SB, Emery P, Dorrier C, Furst DE.
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [Abstract] [Full Text] [Related]

  • 20. A randomised placebo controlled trial of delipidated, deglycolipidated Mycobacterium vaccae as immunotherapy for psoriatic arthritis.
    Dalbeth N, Yeoman S, Dockerty JL, Highton J, Robinson E, Tan PL, Herman D, McQueen FM.
    Ann Rheum Dis; 2004 Jun; 63(6):718-22. PubMed ID: 15140780
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.